vs
Side-by-side financial comparison of ESAB Corp (ESAB) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
ESAB Corp is the larger business by last-quarter revenue ($727.8M vs $493.8M, roughly 1.5× Pediatrix Medical Group, Inc.). ESAB Corp runs the higher net margin — 7.5% vs 6.8%, a 0.7% gap on every dollar of revenue. On growth, ESAB Corp posted the faster year-over-year revenue change (8.5% vs -1.7%). Over the past eight quarters, ESAB Corp's revenue compounded faster (2.8% CAGR vs -0.1%).
ESAB, Elektriska Svetsnings-Aktiebolaget, is an American-Swedish industrial company.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
ESAB vs MD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $727.8M | $493.8M |
| Net Profit | $54.8M | $33.7M |
| Gross Margin | 37.0% | — |
| Operating Margin | 14.6% | 9.9% |
| Net Margin | 7.5% | 6.8% |
| Revenue YoY | 8.5% | -1.7% |
| Net Profit YoY | 2.1% | 10.5% |
| EPS (diluted) | $0.90 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $727.8M | $493.8M | ||
| Q3 25 | $715.6M | $492.9M | ||
| Q2 25 | $678.1M | $468.8M | ||
| Q1 25 | — | $458.4M | ||
| Q4 24 | $670.8M | $502.4M | ||
| Q3 24 | $673.3M | $511.2M | ||
| Q2 24 | $707.1M | $504.3M | ||
| Q1 24 | $689.7M | $495.1M |
| Q4 25 | $54.8M | $33.7M | ||
| Q3 25 | $66.9M | $71.7M | ||
| Q2 25 | $67.4M | $39.3M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | $53.7M | $30.5M | ||
| Q3 24 | $68.2M | $19.4M | ||
| Q2 24 | $82.9M | $-153.0M | ||
| Q1 24 | $60.0M | $4.0M |
| Q4 25 | 37.0% | — | ||
| Q3 25 | 37.2% | — | ||
| Q2 25 | 37.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 38.5% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 38.2% | — | ||
| Q1 24 | 37.0% | — |
| Q4 25 | 14.6% | 9.9% | ||
| Q3 25 | 15.2% | 13.8% | ||
| Q2 25 | 16.2% | 12.8% | ||
| Q1 25 | — | 7.0% | ||
| Q4 24 | 16.6% | 7.8% | ||
| Q3 24 | 15.7% | 6.6% | ||
| Q2 24 | 16.9% | -31.3% | ||
| Q1 24 | 16.0% | 3.2% |
| Q4 25 | 7.5% | 6.8% | ||
| Q3 25 | 9.3% | 14.5% | ||
| Q2 25 | 9.9% | 8.4% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | 8.0% | 6.1% | ||
| Q3 24 | 10.1% | 3.8% | ||
| Q2 24 | 11.7% | -30.3% | ||
| Q1 24 | 8.7% | 0.8% |
| Q4 25 | $0.90 | $0.40 | ||
| Q3 25 | $1.09 | $0.84 | ||
| Q2 25 | $1.10 | $0.46 | ||
| Q1 25 | — | $0.24 | ||
| Q4 24 | $0.87 | $0.37 | ||
| Q3 24 | $1.11 | $0.23 | ||
| Q2 24 | $1.35 | $-1.84 | ||
| Q1 24 | $0.98 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $218.2M | $375.2M |
| Total DebtLower is stronger | $1.3B | $570.5M |
| Stockholders' EquityBook value | $2.1B | $865.9M |
| Total Assets | $4.9B | $2.2B |
| Debt / EquityLower = less leverage | 0.63× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $218.2M | $375.2M | ||
| Q3 25 | $258.2M | $340.1M | ||
| Q2 25 | $291.3M | $224.7M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | $249.4M | $229.9M | ||
| Q3 24 | $253.7M | $103.8M | ||
| Q2 24 | $228.5M | $19.4M | ||
| Q1 24 | $76.5M | $8.0M |
| Q4 25 | $1.3B | $570.5M | ||
| Q3 25 | $1.1B | $577.2M | ||
| Q2 25 | $1.1B | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | $1.1B | $597.1M | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $992.8M | — |
| Q4 25 | $2.1B | $865.9M | ||
| Q3 25 | $2.1B | $890.7M | ||
| Q2 25 | $1.9B | $833.8M | ||
| Q1 25 | — | $789.2M | ||
| Q4 24 | $1.8B | $764.9M | ||
| Q3 24 | $1.8B | $732.5M | ||
| Q2 24 | $1.7B | $706.5M | ||
| Q1 24 | $1.6B | $856.2M |
| Q4 25 | $4.9B | $2.2B | ||
| Q3 25 | $4.4B | $2.2B | ||
| Q2 25 | $4.2B | $2.1B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | $4.0B | $2.2B | ||
| Q3 24 | $4.1B | $2.1B | ||
| Q2 24 | $4.0B | $2.0B | ||
| Q1 24 | $3.8B | $2.2B |
| Q4 25 | 0.63× | 0.66× | ||
| Q3 25 | 0.51× | 0.65× | ||
| Q2 25 | 0.55× | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | 0.60× | 0.78× | ||
| Q3 24 | 0.59× | — | ||
| Q2 24 | 0.63× | — | ||
| Q1 24 | 0.61× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $81.5M | $114.1M |
| Free Cash FlowOCF − Capex | $70.3M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 1.5% | — |
| Cash ConversionOCF / Net Profit | 1.49× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $238.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $81.5M | $114.1M | ||
| Q3 25 | $46.6M | $137.3M | ||
| Q2 25 | $35.4M | $137.2M | ||
| Q1 25 | — | $-117.5M | ||
| Q4 24 | $126.9M | $133.0M | ||
| Q3 24 | $101.0M | $91.8M | ||
| Q2 24 | $83.0M | $107.0M | ||
| Q1 24 | $44.5M | $-125.2M |
| Q4 25 | $70.3M | — | ||
| Q3 25 | $37.4M | — | ||
| Q2 25 | $28.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $102.2M | — | ||
| Q3 24 | $90.4M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $37.1M | — |
| Q4 25 | 9.7% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 4.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 15.2% | — | ||
| Q3 24 | 13.4% | — | ||
| Q2 24 | 10.5% | — | ||
| Q1 24 | 5.4% | — |
| Q4 25 | 1.5% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 1.6% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.49× | 3.39× | ||
| Q3 25 | 0.70× | 1.91× | ||
| Q2 25 | 0.53× | 3.49× | ||
| Q1 25 | — | -5.66× | ||
| Q4 24 | 2.36× | 4.36× | ||
| Q3 24 | 1.48× | 4.72× | ||
| Q2 24 | 1.00× | — | ||
| Q1 24 | 0.74× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
